Anthracycline cardiotoxicity: Why are we still interested?

ONCOLOGY

Volumn 23, Issue 3, 2009, Pages 234-239

  Ewer, Steven M ^a   Ewer, Michael S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; DOXORUBICIN; TRASTUZUMAB; TROPONIN I;

BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CELL DEATH; CONGESTIVE HEART FAILURE; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; HEART EJECTION FRACTION; HUMAN; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

ANTHRACYCLINES; HEART DISEASES; HUMANS; NEOPLASMS;

EID: 64549141601     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study (abstract 1). Breast Cancer Res Treat 94(suppl 1):S5, 2005.
2. Cardinale D, Sandri MT, Martinoni A, et al: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517-522, 2000.
3. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfanction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005.
4. Slamon D J, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.
5. Rastogi P, Jeong J, Geyer CE, et al: Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→ paclitaxel (T) vs. AC→T with trastuzumab (H) (abstract LBA513). J Clin Oncol 25:6s, 2007.
6. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007.
7. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-920, 2006.